| Industry | Pharmaceuticals |
|---|---|
| Defunct | 2013 |
| Headquarters | , United States |
| Products | Pegloticase, oxandrolone |
| Website | http://www.savientpharma.com/ |
Savient Pharmaceuticals was a New Jersey-based biopharmaceutical company. Its lead product, pegloticase, was a biologic drug for treatment resistant chronic gout, which it marketed beginning in 2011.[1] It also marketed oxandrolone beginning in 1995.[2]
Savient was incorporated in 1980 as Bio-Technology General Corp and changed its name in 2003.[3]
Savient later focused on commercializing pegloticase in the United States and completing the development and seeking regulatory approval in the European Union.[citation needed] The company also sold branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. John H. Johnson was CEO from February 2011 until February 2012, formerly employed by Imclone Systems.[4]
Savient declared bankruptcy in 2013.[5] The drug was selling at $5,390 per vial—around $30,000 for a three-month course of treatment—at the time Savient went under.[6]
Savient was then bought by Crealta.[6] In 2015, Crealta was able to sell the asset to Horizon Pharma for $510 million that year.[6]